Prothena Corporation plc (NASDAQ: PRTA)’s stock price has plunge by 0.71relation to previous closing price of 5.66. Nevertheless, the company has seen a 8.37% surge in its stock price over the last five trading sessions. businesswire.com reported 2025-06-16 that DUBLIN–(BUSINESS WIRE)—- $PRTA #prothena–Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson’s disease.
Is It Worth Investing in Prothena Corporation plc (NASDAQ: PRTA) Right Now?
The stock has a 36-month beta value of -0.06. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 3 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for PRTA is 42.32M, and at present, short sellers hold a 10.43% of that float. On June 18, 2025, the average trading volume of PRTA was 1.41M shares.
PRTA’s Market Performance
PRTA stock saw a decrease of 8.37% in the past week, with a monthly decline of -20.61% and a quarterly a decrease of -55.57%. The volatility ratio for the week is 5.38%, and the volatility levels for the last 30 days are 9.07% for Prothena Corporation plc (PRTA). The simple moving average for the last 20 days is 5.88% for PRTA stock, with a simple moving average of -58.35% for the last 200 days.
Analysts’ Opinion of PRTA
Many brokerage firms have already submitted their reports for PRTA stocks, with BofA Securities repeating the rating for PRTA by listing it as a “Underperform.” The predicted price for PRTA in the upcoming period, according to BofA Securities is $4 based on the research report published on May 28, 2025 of the current year 2025.
Jefferies gave a rating of “Hold” to PRTA, setting the target price at $6 in the report published on May 27th of the current year.
PRTA Trading at -23.25% from the 50-Day Moving Average
After a stumble in the market that brought PRTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.58% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PRTA starting from EcoR1 Capital, LLC, who sale 3,317,938 shares at the price of $8.36 back on May 02 ’25. After this action, EcoR1 Capital, LLC now owns 8,266,342 shares of Prothena Corporation plc, valued at $27,744,929 using the latest closing price.
EcoR1 Capital, LLC, the 10% Owner of Prothena Corporation plc, sale 1,984,053 shares at $7.64 during a trade that took place back on May 06 ’25, which means that EcoR1 Capital, LLC is holding 5,304,596 shares at $15,164,712 based on the most recent closing price.
Stock Fundamentals for PRTA
Current profitability levels for the company are sitting at:
- -1.0 for the present operating margin
- 0.58 for the gross margin
The net margin for Prothena Corporation plc stands at -0.8. The total capital return value is set at -0.31. Equity return is now at value -23.46, with -19.72 for asset returns.
Based on Prothena Corporation plc (PRTA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -12.78.
Currently, EBITDA for the company is -154.56 million with net debt to EBITDA at 2.96. When we switch over and look at the enterprise to sales, we see a ratio of -0.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.00.
Conclusion
To sum up, Prothena Corporation plc (PRTA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
